Cataño Juan Carlos, Morales Milena
Infectious Diseases Section, Internal Medicine Department, University of Antioquia School of Medicine, Calle 15 Sur # 48 - 130, Medellín, Colombia,
Rheumatol Int. 2015 Sep;35(9):1549-53. doi: 10.1007/s00296-015-3249-6. Epub 2015 Mar 13.
The use of biological therapy has been linked with an increased risk of tuberculosis (TB) reactivation. The aim of this study was to present the follow-up results for isoniazid (INH) chemoprophylaxis in patients receiving different biological therapies. In this prospective observational study, patients with latent tuberculosis infection (LTBI) were given INH chemoprophylaxis between 2 and 9 months prior to the beginning of biological therapy. All patients were followed up monthly for any signs or symptoms of active TB or INH toxicity. A total of 221 patients, 122 females (55.2 %), with a mean age of 46.8 ± 11.3 years (16-74) were enrolled. LTBI was identified in 218 patients (98.7 %), all of whom received INH chemoprophylaxis. Seven patients (3.2 %) developed active tuberculosis, and 32 (17.2 %) patients developed intolerance or toxicity related to INH. Chemoprophylaxis with INH seems to be effective and safe for the prevention of most TB reactivation in individuals with LTBI, but toxicity must be monitored during follow-up.
生物疗法的使用与结核病（TB）复发风险增加有关。本研究的目的是介绍接受不同生物疗法的患者中异烟肼（INH）化学预防的随访结果。在这项前瞻性观察研究中，潜伏性结核感染（LTBI）患者在开始生物疗法前2至9个月接受INH化学预防。所有患者每月进行随访，观察是否有活动性结核的任何体征或症状或INH毒性。共纳入221例患者，其中女性122例（55.2%），平均年龄46.8±11.3岁（16 - 74岁）。218例患者（98.7%）被诊断为LTBI，所有患者均接受了INH化学预防。7例患者（3.2%）发生活动性结核，32例患者（17.2%）出现与INH相关的不耐受或毒性反应。INH化学预防对于预防LTBI个体中的大多数结核复发似乎是有效且安全的，但随访期间必须监测毒性反应。
